---

Background and objectives: Docetaxel is a chemotherapeutic agent commonly used for treatment of many cancers, including esophageal squamous cell carcinoma. Docetaxel induces G2/M phase cell cycle arrest and ultimately cell death. In this study, we aimed to assess the effects of docetaxel on YM1 cells considering exposure time and dose.
Methods: After calculating the doubling time of YM1 cells, the anti-proliferative effect of different concentrations of docetaxel () [A1]  after 24, 48 and 72 hours was assessed by the standard colorimetric assay. In addition, the effect of docetaxel on cell cycle was evaluated by flow cytometry.
Results: The results showed that docetaxel toxicity was not significant until 24 hours at the tested concentrations (P>0.05). In addition, the effect of docetaxel on the cells was time-dependent at all tested concentrations. Overall, the duration of exposure to docetaxel had more significant role in docetaxel toxicity in YM1 cells compared to concentration.
Conclusion: Our findings suggest that the cytotoxicity of docetaxel on YM1 cells is time-dependent.

---

Background and Objectives: Gastric cancer (GC), particularly adenocarcinoma, remains a global health burden with high mortality due to late-stage diagnosis and limited reliable biomarkers for disease monitoring. Lipid metabolism plays a crucial role in tumor biology, and serum lipid-related markers, including apolipoproteins, have been suggested as potential non-invasive indicators of tumor progression. This study aimed to evaluate the association between serum lipid profiles and tumor stage and histological grade in patients with gastric adenocarcinoma.
Methods: Fifty patients diagnosed with gastric adenocarcinoma were enrolled. Serum levels of total cholesterol, triglycerides, HDL-C, LDL-C, ApoA1, and ApoB were measured. Patients were categorized into early (stages I–II) and advanced (stages III–IV) tumor stages, as well as into moderately differentiated versus poorly differentiated grades. The Shapiro-Wilk test was used to assess data normality. Parametric and non-parametric tests were applied accordingly. A p-value < 0.05 was considered statistically significant.
Results: ApoB was the only parameter showing a significant association with tumor stage. Patients with advanced-stage GC had significantly lower mean ApoB levels compared to those in early stages (52.4 ± 2.6 vs. 63.4 ± 5.2 mg/dl, p = 0.042). No statistically significant differences were observed in ApoA1, HDL-C, total cholesterol, triglycerides, LDL-C, or VLDL, for either tumor stage or histological grade.
Conclusion: ApoB levels appear to decline with advancing tumor stage in gastric adenocarcinoma, suggesting a potential role as a marker to evaluate disease burden. While no association was found with tumor grade, further validation in larger prospective studies incorporating metabolic and inflammatory covariates is warranted.